Target intelligence / Profile preview

Immunoglobulin kappa variable 2-24 (IGKV2-24)

Target
IGKV2-24
Molecular classification
Immunoglobulin (antibody) gene segment, Variable domain of immunoglobulin light chain
01

Overview

Immunoglobulin kappa variable 2-24 (IGKV2-24) is a gene segment encoding the variable region of the kappa light chain in immunoglobulins (antibodies)[1][2][4][5][6]. This variable domain participates in antigen recognition and is generated by V-(D)-J recombination during B cell development, contributing to the diversity of antibodies in the adaptive immune system[2][5]. IGKV2-24 is not a stand-alone receptor, enzyme, or direct therapeutic target, but is a functional part of the antibody molecules either as membrane-bound B cell receptors or as secreted antibodies. Its main role is in forming the antigen-binding site in conjunction with immunoglobulin heavy chains, playing a central part in humoral immunity[2][4][5][6]. It is relevant in clinical immunology for evaluating B cell clonality and may be implicated in studies of immune repertoire or diagnostics but is not directly targeted by drugs[2][4][6].

Other names
IGKV2-24KV224A23IGKV224Immunoglobulin kappa chain V-II regionA0A0C4DH68
02

Biological functions

Antigen recognitionImmune response
03

Disease associations

Other (contributes to the diversity of antibodies; not directly implicated as a driver in specific diseases, but relevant in contexts such as autoimmune disorders and lymphoproliferative diseases where immunoglobulin gene usage is analyzed)
04

Biomarkers

Somatic mutations or gene rearrangements involving IGKV2-24 may be used as B cell clonality markers in lymphoma or leukemia diagnostics

Beyond the preview

Go deeper on Immunoglobulin kappa variable 2-24 (IGKV2-24).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 2-24 (IGKV2-24).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call